Clinical Trial Update: M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial compares the melanoma vaccine M-Vax plus low-dose interleukin-2 against placebo in patients with stage IV/metastatic melanoma; current …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• M-Vax

Snippet

Sponsor: AVAX Technologies | Conditions: Melanoma | Phase 3 | Status: UNKNOWN